Male (based on chromosomal composition at birth) and aged greater than or equal to (\>=) 18 years.
Must have a histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
Must have documented metastatic hormone-sensitive prostate cancer (mHSPC)
Must have agreed with the treating physician to initiate treatment with apalutamide (plus androgen-deprivation therapy \[ADT\]) in accordance with the current product characteristics summary, based on the physician's decision, prior to study inclusion
Able to understand the content of the patient information sheet and has provided oral consent for data collection. Has received the information sheet and has not objected to data collection
Must have a baseline prostate-specific antigen (PSA) level collected prior to the first administration of apalutamide.
Must agree to complete adherence and quality-of-life questionnaires during the study, including before the first administration of apalutamide
You may not be if
Has already received or is currently receiving apalutamide, or any other androgen receptor pathway inhibitor (ARPI; including but not limited to abiraterone acetate, darolutamide, and enzalutamide) or chemotherapy for mHSPC
Has received an investigational drug (including vaccines) or used an invasive investigational medical device within 90 days prior to study start or data collection
Is currently receiving active treatment for prostate cancer as part of an interventional study
Has received ADT for mHSPC for more than 4 months prior to starting apalutamide treatment
Has experienced progression under ADT (and thus became castration-resistant) before starting apalutamide treatment
Beneficiary of State Medical Aid \[AME\]
Does not speak/read French
Under guardianship or curatorship
Under judicial protection
Clareo Health | A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France
